InSightec Panel Acquiesces Despite Efficacy, Control Group Concerns
This article was originally published in The Gray Sheet
Executive Summary
Labeling for InSightec's ExAblate 2000 non-invasive uterine fibroid treatment should describe "mitigations" to minimize the risk of nerve damage during the procedure, FDA advisory panel members recommend
You may also be interested in...
InSightec ExAblate 2000 Approved For Uterine Fibroids; 3-Year Study Required
FDA approval conditions for InSightec's ExAblate 2000 uterine fibroid ultrasound treatment respond to advisory panel concerns about short-term safety and efficacy data in the original PMA submission
InSightec ExAblate 2000 Approved For Uterine Fibroids; 3-Year Study Required
FDA approval conditions for InSightec's ExAblate 2000 uterine fibroid ultrasound treatment respond to advisory panel concerns about short-term safety and efficacy data in the original PMA submission
Uterine Artery Embolization Long-Term Efficacy Challenged By NICE Panel
Evidence on the degree and permanence of uterine artery embolization's efficacy in fibroid treatment is insufficient to support liberal use, according to an advisory panel of the UK's National Institute for Clinical Excellence